Tandem Diabetes Care, Inc. is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. The Company takes an innovative, user-centric approach to the design, development and commercialization of products for people with diabetes who use insulin. Tandem's flagship product, the t:slim X2™ insulin pump, is capable of remote software updates using a personal computer and features integrated continuous glucose monitoring. Tandem is based in San Diego, California.

Company profile
Ticker
TNDM
Exchange
Website
CEO
John Sheridan
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
3M • Baxter International • Boston Scientific • Stryker • Becton, Dickinson And • Teleflex • Resmed • Haemonetics • Hill-Rom • Nuvasive ...
SEC CIK
Corporate docs
Subsidiaries
Tandem Diabetes Care Canada, Inc. • Sugarmate Inc. ...
IRS number
204327508
TNDM stock data
Analyst ratings and price targets
Current price
Average target
$55.00
Low target
$43.00
High target
$70.00
Wells Fargo
Upgraded
$43.00
Raymond James
Maintains
$52.00
Piper Sandler
Maintains
$70.00
Latest filings (excl ownership)
8-K
Tandem Diabetes Care Completes Acquisition of Insulin Patch Pump Developer, AMF Medical
23 Jan 23
8-K
Tandem Diabetes Care Reports Preliminary, Unaudited 2022 Sales and Reaffirms 2023 Outlook
10 Jan 23
8-K
Tandem Diabetes Care to Acquire Insulin Patch Pump Developer, AMF Medical
13 Dec 22
10-Q
2022 Q3
Quarterly report
2 Nov 22
8-K
Tandem Diabetes Care Announces Third Quarter 2022 Financial Results
2 Nov 22
10-Q
2022 Q2
Quarterly report
3 Aug 22
8-K
Tandem Diabetes Care Announces Second Quarter 2022 Financial Results
3 Aug 22
8-K
Tandem Diabetes Care Welcomes Two New Members to Board of Directors
16 Jun 22
8-K
Submission of Matters to a Vote of Security Holders
27 May 22
SD
Conflict minerals disclosure
27 May 22
Transcripts
TNDM
Earnings call transcript
2022 Q3
3 Nov 22
TNDM
Earnings call transcript
2022 Q2
4 Aug 22
TNDM
Earnings call transcript
2022 Q1
4 May 22
TNDM
Earnings call transcript
2021 Q4
23 Feb 22
TNDM
Earnings call transcript
2021 Q3
4 Nov 21
TNDM
Earnings call transcript
2021 Q2
5 Aug 21
TNDM
Earnings call transcript
2021 Q1
6 May 21
TNDM
Earnings call transcript
2020 Q4
25 Feb 21
TNDM
Earnings call transcript
2020 Q3
5 Nov 20
TNDM
Earnings call transcript
2020 Q2
31 Jul 20
Latest ownership filings
Financial summary
Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 123.79 mm | 123.79 mm | 123.79 mm | 123.79 mm | 123.79 mm | 123.79 mm |
Cash burn (monthly) | (no burn) | (no burn) | 15.83 mm | 5.35 mm | (no burn) | (no burn) |
Cash used (since last report) | n/a | n/a | 63.68 mm | 21.50 mm | n/a | n/a |
Cash remaining | n/a | n/a | 60.11 mm | 102.29 mm | n/a | n/a |
Runway (months of cash) | n/a | n/a | 3.8 | 19.1 | n/a | n/a |
Institutional ownership, Q3 2022
13F holders | Current |
---|---|
Total holders | 302 |
Opened positions | 39 |
Closed positions | 72 |
Increased positions | 102 |
Reduced positions | 117 |
13F shares | Current |
---|---|
Total value | 3.07 bn |
Total shares | 69.01 mm |
Total puts | 394.01 k |
Total calls | 322.00 k |
Total put/call ratio | 1.2 |
Largest owners | Shares | Value |
---|---|---|
FMR | 8.97 mm | $429.37 mm |
Vanguard | 6.19 mm | $296.40 mm |
BLK Blackrock | 6.09 mm | $291.56 mm |
Capital World Investors | 4.56 mm | $217.99 mm |
Corrib Capital Management | 4.50 mm | $13.14 mm |
Champlain Investment Partners | 3.12 mm | $149.48 mm |
Alger Associates | 2.69 mm | $117.15 mm |
Brown Capital Management | 2.01 mm | $96.19 mm |
Eminence Capital | 1.59 mm | $76.12 mm |
BLVGF Bellevue | 1.57 mm | $74.93 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
4 Jan 23 | Rajwant Sodhi | Common Stock | Option exercise | Acquire M | No | No | 0 | 1,069 | 0.00 | 2,873 |
4 Jan 23 | Rajwant Sodhi | RSU Common Stock | Option exercise | Acquire M | No | No | 0 | 1,069 | 0.00 | 1,070 |
16 Dec 22 | David B Berger | Common Stock | Sell | Dispose S | No | No | 40.25 | 10,000 | 402.50 k | 3,029 |
16 Dec 22 | David B Berger | Common Stock | Option exercise | Acquire M | No | No | 18.86 | 10,000 | 188.60 k | 13,029 |
16 Dec 22 | David B Berger | Stock Option Common Stock | Option exercise | Acquire M | No | No | 18.86 | 10,000 | 188.60 k | 10,000 |
15 Dec 22 | Rick Carpenter | Common Stock | Payment of exercise | Dispose F | No | No | 40.42 | 562 | 22.72 k | 1,395 |
15 Dec 22 | Rick Carpenter | Common Stock | Option exercise | Acquire M | No | No | 0 | 1,624 | 0.00 | 1,957 |
15 Dec 22 | Rick Carpenter | RSU Common Stock | Option exercise | Acquire M | No | No | 0 | 1,624 | 0.00 | 4,871 |
15 Dec 22 | David B Berger | Common Stock | Sell | Dispose S | No | No | 40.32 | 15,000 | 604.80 k | 3,029 |
15 Dec 22 | David B Berger | Common Stock | Option exercise | Acquire M | No | No | 18.86 | 15,000 | 282.90 k | 18,029 |
News
Benzinga's Top Ratings Upgrades, Downgrades For January 26, 2023
26 Jan 23
Wolfe Research Initiates Coverage On Tandem Diabetes Care with Peer Perform Rating
26 Jan 23
CommVault Systems, Halozyme Therapeutics And Other Big Stocks Moving Lower On Wednesday
11 Jan 23
Tandem Diabetes Acquires Swiss Based Insulin Patch Pump Developer
13 Dec 22
Tandem Diabetes Care to Acquire Insulin Patch Pump Developer, AMF Medical; Includes Previous Investment Of CHF 8M, Cash Payment Of CHF 26.4M Due At Closing, Additional Contingent Payments Of Up To CHF 129.6M
13 Dec 22
Press releases
Tandem Diabetes Care to Announce Fourth Quarter and Full Year 2022 Financial Results on February 22, 2023
19 Jan 23
Tandem Diabetes Care Reports Preliminary, Unaudited 2022 Sales and Reaffirms 2023 Outlook
10 Jan 23
Tandem Diabetes Care to Present at the 41st Annual J.P. Morgan Healthcare Conference
3 Jan 23
Tandem Diabetes Care to Acquire Insulin Patch Pump Developer, AMF Medical
13 Dec 22
Tandem Diabetes Care Earns Great Place to Work Certification™
16 Nov 22